Literature DB >> 21937640

Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.

Naushad Ali1, Heba Allam, Randal May, Sripathi M Sureban, Michael S Bronze, Ted Bader, Shahid Umar, Srikant Anant, Courtney W Houchen.   

Abstract

Hepatitis C virus (HCV) infection is a prominent risk factor for the development of hepatocellular carcinoma (HCC). Similar to most solid tumors, HCCs are believed to contain poorly differentiated cancer stem cell-like cells (CSCs) that initiate tumorigenesis and confer resistance to chemotherapy. In these studies, we demonstrate that the expression of an HCV subgenomic replicon in cultured cells results in the acquisition of CSC traits. These traits include enhanced expression of doublecortin and CaM kinase-like-1 (DCAMKL-1), Lgr5, CD133, α-fetoprotein, cytokeratin-19 (CK19), Lin28, and c-Myc. Conversely, curing of the replicon from these cells results in diminished expression of these factors. The putative stem cell marker DCAMKL-1 is also elevated in response to the overexpression of a cassette of pluripotency factors. The DCAMKL-1-positive cells isolated from hepatoma cell lines by fluorescence-activated cell sorting (FACS) form spheroids in Matrigel. The HCV RNA abundance and NS5B levels are significantly reduced by the small interfering RNA (siRNA)-led depletion of DCAMKL-1. We further demonstrate that HCV replicon-expressing cells initiate distinct tumor phenotypes compared to the tumors initiated by parent cells lacking the replicon. This HCV-induced phenotype is characterized by high-level expression/coexpression of DCAMKL-1, CK19, α-fetoprotein, and active c-Src. The results obtained by the analysis of liver tissues from HCV-positive patients and liver tissue microarrays reiterate these observations. In conclusion, chronic HCV infection appears to predispose cells toward the path of acquiring cancer stem cell-like traits by inducing DCAMKL-1 and hepatic progenitor and stem cell-related factors. DCAMKL-1 also represents a novel cellular target for combating HCV-induced hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21937640      PMCID: PMC3209402          DOI: 10.1128/JVI.05920-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

Review 1.  Clinical practice. Chronic hepatitis C infection.

Authors:  Hugo R Rosen
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

Review 2.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

3.  Hepatitis C virus infection impairs IRF-7 translocation and Alpha interferon synthesis in immortalized human hepatocytes.

Authors:  Amit Raychoudhuri; Shubham Shrivastava; Robert Steele; Srikanta Dash; Tatsuo Kanda; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

4.  Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma.

Authors:  Hyun Goo Woo; Jeong-Hoon Lee; Jung-Hwan Yoon; Chung Yong Kim; Hyo-Suk Lee; Ja June Jang; Nam-Joon Yi; Kyung-Suk Suh; Kuhn Uk Lee; Eun Sung Park; Snorri S Thorgeirsson; Yoon Jun Kim
Journal:  Cancer Res       Date:  2010-04-15       Impact factor: 12.701

5.  Effect of alpha interferon on the hepatitis C virus replicon.

Authors:  J T Guo; V V Bichko; C Seeger
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 6.  New insights into structure and replication of the hepatitis C virus and clinical implications.

Authors:  Marion Poenisch; Ralf Bartenschlager
Journal:  Semin Liver Dis       Date:  2010-10-19       Impact factor: 6.115

Review 7.  Hepatitis A and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses.

Authors:  Lin Qu; Stanley M Lemon
Journal:  Semin Liver Dis       Date:  2010-10-19       Impact factor: 6.115

8.  DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization.

Authors:  P T Lin; J G Gleeson; J C Corbo; L Flanagan; C A Walsh
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

9.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

10.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

View more
  48 in total

Review 1.  Cervical cancer stem cells.

Authors:  Tingting Yao; Rongbiao Lu; Yizhen Zhang; Ya Zhang; Chenyang Zhao; Rongchun Lin; Zhongqiu Lin
Journal:  Cell Prolif       Date:  2015-12       Impact factor: 6.831

Review 2.  Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Nai-Kong V Cheung
Journal:  Cancer Lett       Date:  2017-04-17       Impact factor: 8.679

Review 3.  Hepatocellular carcinoma: Where are we?

Authors:  Roberto Mazzanti; Umberto Arena; Renato Tassi
Journal:  World J Exp Med       Date:  2016-02-20

4.  Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro.

Authors:  Craig Gedye; Tracy Cardwell; Nektaria Dimopoulos; Bee Shin Tan; Heather Jackson; Suzanne Svobodová; Matthew Anaka; Andreas Behren; Christopher Maher; Oliver Hofmann; Winston Hide; Otavia Caballero; Ian D Davis; Jonathan Cebon
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

Review 5.  Lin28 and let-7: roles and regulation in liver diseases.

Authors:  Kelly McDaniel; Chad Hall; Keisaku Sato; Terry Lairmore; Marco Marzioni; Shannon Glaser; Fanyin Meng; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-24       Impact factor: 4.052

6.  SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases.

Authors:  Ta-Chiang Liu; Neeta Vachharajani; William C Chapman; Elizabeth M Brunt
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

Review 7.  APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases.

Authors:  Charles B Nguyen; Courtney W Houchen; Naushad Ali
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

Review 8.  New insights into pancreatic cancer stem cells.

Authors:  Chinthalapally V Rao; Altaf Mohammed
Journal:  World J Stem Cells       Date:  2015-04-26       Impact factor: 5.326

9.  Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line.

Authors:  Lianna Li; Charles F Bellows
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

Review 10.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.